Elsevier

Clinical Therapeutics

Volume 23, Issue 7, July 2001, Pages 998-1017
Clinical Therapeutics

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

https://doi.org/10.1016/S0149-2918(01)80087-4Get rights and content

Abstract

Background: The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD).

Objective: On the basis of the results of randomized clinical trials, this study sought to estimate healing and relapse rates in acute and maintenance treatment of GERD with the newer PPIs compared with omeprazole, the histamine2-receptor antagonist ranitidine (the most frequent non-PPI comparator in studies of PPIs), and placebo.

Methods: A search of MEDLINE® was conducted to identify randomized, controlled clinical trials that included a PPI in ≥1 treatment arm and assessed the healing of erosive esophagitis endoscopically. The primary outcome for studies of acute therapy was healing rate, and the primary outcome for studies of maintenance therapy was relapse rate.

Results: Fifty-three studies were identified, of which 38 involved acute therapy (12 excluded) and 15 maintenance therapy. None of the studies of pantoprazole met the inclusion criteria for maintenance therapy. The 8-week overall healing rate ratios in the comparison of newer PPIs with omeprazole 20 mg/d were as follows: lansoprazole 30 mg/d, 1.02 (95% CI, 0.98–1.06); rabeprazole 20 mg/d, 0.93 (95% CI, 0.87–1.00); and pantoprazole 40 mg/d, 0.98 (95% CI, 0.90–1.07). In the comparison of any PPI with ranitidine 300 mg/d, the ratios were as follows: lansoprazole, 1.62 (95% CI, 1.46–1.76); rabeprazole, 1.36 (95% CI, 1.20–1.54); pantoprazole, 1.60 (95% CI, 1.33–1.96); and omeprazole, 1.58 (95% CI, 1.41–1.78). Relapse rates over 1 year of treatment were similar between lansoprazole and rabeprazole. Compared with ranitidine, there were statistically significant differences in the rates of resolution of heartburn symptoms (P < 0.002), ulcer healing (P < 0.05), and relapse (P < 0.01). Similar results were seen in the comparison of PPIs with placebo in terms of rates of resolution of heartburn symptoms (P < 0.01), ulcer healing (P < 0.001), and relapse (P < 0.006).

Conclusions: In this study, the newer PPIs were of similar efficacy to omeprazole in terms of heartburn control, healing rates, and relapse rates. All the PPIs were superior to ranitidine and placebo in healing erosive esophagitis and decreasing relapse rates.

References (70)

  • JP Galmiche et al.

    Treatment of gastro-oesophageal reflux disease in adults

    Br Med J

    (1998)
  • DO Castell et al.

    Gastro-esophageal reflux disease. Current strategies for patient management

    Arch Fam Med

    (1996)
  • M Wienbeck et al.

    Epidemiology of reflux disease and reflux oesophagitis

    Scand J Gastroenterol

    (1989)
  • JF Johanson

    Epidemiology of esophageal and supraesophageal reflux injuries

    Am J Med

    (2000)
  • SJ Spechler

    Epidemiology and natural history of gastro-oesophageal reflux disease

    Digestion

    (1992)
  • PO Katz

    Pathogenesis and management of gastroesophageal reflux disease

    J Clin Gastroenterol

    (1991)
  • AB Thomson et al.

    The Second Canadian Gastroesophageal Reflux Disease Consensus: Moving forward to new concepts

    Can J Gastroenterol

    (1998)
  • G Holtmann et al.

    Are proton pump inhibitors superior to H2-receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons [in German]

    Z Gastroenterol

    (1996)
  • N Chiba

    Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview

    Can J Gastroenterol

    (1997)
  • TA Lampkin et al.

    Omeprazole: A novel antisecretory agent for the treatment of acid-peptic disorders

    DICP

    (1990)
  • OS Miettinen

    Theoretical epidemiology

  • S Greenland et al.

    Testing homogeneity

  • AL Blum

    Omeprazole is superior to ranitidine in curing and further managing patients with heartburn

    Gut

    (1997)
  • BP Hazenberg et al.

    Omeprazole versus ranitidine in the treatment of symptomatic mild reflux oesophagitis. A Dutch multi-centre trial

    Gut

    (1995)
  • ML Cloud et al.

    Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)

    Dig Dis Sci

    (1998)
  • JH McCarthy et al.

    Omeprazole in the treatment of reflux oesophagitis

    Aust New Zealand J Med

    (1986)
  • JE Richter et al.

    Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis

    Arch Intern Med

    (2000)
  • JE Richter et al.

    Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

    Arch Intern Med

    (2000)
  • PN Maton et al.

    Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease—a prospective, controlled trial

    Aliment Pharmacol Ther

    (1999)
  • JG Hatlebakk et al.

    Heartburn treatment in primary care: Randomised, double blind study for 8 weeks

    Br Med J

    (1999)
  • L Lundell et al.

    Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to ‘standard doses’ of H2-receptor antagonists

    Aliment Pharmacol Ther

    (1990)
  • CP Dekkers et al.

    Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastrooesophageal reflux disease

    Aliment Pharmacol Ther

    (1999)
  • JC Delchier et al.

    Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

    Scand J Gastroenterol

    (2000)
  • R Corinaldesi et al.

    Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study

    Aliment Pharmacol Ther

    (1995)
  • J Mossner et al.

    A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicenter trial

    Aliment Pharmacol Ther

    (1995)
  • Cited by (0)

    View full text